￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

Oncology

Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
EGFR exon 20 mutations usher in the first oral targeted drug, mobotinib

2025-10-19 11:44:20

Check Details
Efficacy and safety data of Rybrevant in the treatment of lung cancer show anti-tumor activity!

2025-10-19 11:44:20

Check Details
Where can I buy Rybrevant? What is the dosage of Rybrevant?

2025-10-19 11:44:20

Check Details
Can dacomitinib be reimbursed by medical insurance? What should I pay attention to?

2025-10-19 11:44:20

Check Details
FDA announces that Rybrevant, the first targeted drug for lung cancer EGFR20ins, has been approved for marketing

2025-10-19 11:44:20

Check Details
How to use Rybrevant? How long does it take for resistance to develop?

2025-10-19 11:44:20

Check Details
Where can I buy the third-generation ALK inhibitor lorlatinib? What is the effect?

2025-10-19 11:44:20

Check Details
What is the dosage of lorlatinib? What are the side effects?

2025-10-19 11:44:20

Check Details
Targeted drug treatment of EGFR gene mutation lung cancer (1)

2025-10-19 11:44:20

Check Details
Lumakras (AMG510) was approved for marketing - breaking through the milestone of "undruggable" KRAS

2025-10-19 11:44:20

Check Details
FDA approves Amgen’s Lumakras: the world’s first KRAS-targeted therapy!

2025-10-19 11:44:20

Check Details
Detailed survival data and side effects of Lorlatinib!

2025-10-19 11:44:20

Check Details
Category
相关知识